Medtronic automated insulin pump named one of year’s ‘world-changing ideas’
Fast Company, the New York-based business magazine, has named Medtronic’s MiniMed 780G automated insulin delivery system one of North America’s top world-changing ideas. This represents the fourth straight year a piece of Medtronic technology has been included in the annual list, which is designed to honor companies and products that address “the most pressing issues of our time.”
Fast Company’s 2024 World Changing Idea Awards highlighted a total of 12 finalists for its North America category, including the MiniMed 780G system.
“The recognition of the MiniMed 780G system as a World Changing Idea reflects our commitment to simplifying diabetes care and reducing the mental burden of this relentless disease,” Que Dallara, executive vice president and president of Medtronic Diabetes, said in a statement. “We're pleased to receive this honor and will keep working tirelessly to continue empowering individuals with the technology they need to thrive with type 1 diabetes.”
“Diabetes is a very personal disease and no two journeys are the same,” added Ali Dianaty, senior vice president of product innovation and operations with Medtronic Diabetes. “This recognition is a reflection of the tremendous dedication and commitment of the many cross-functional teams that worked day in and day out to bring an idea to life. The MiniMed 780G system is designed to adapt to each individual's unique needs and goals to help reduce the burden of diabetes management, so people with diabetes can spend more time doing what they love.”
The U.S. Food and Drug Administration (FDA) approved the MiniMed 790G device for patients with type 1 diabetes seven years old and older back in April 2023. One new feature available on the pump was meal detection technology, which can deliver insulin in those moments when the user loses track of time or underestimates how a meal may impact their health. According to Medtronic, this feature takes diabetes technology “one step closer to mimicking a healthy pancreas.”
The FDA’s approval was based in part on clinical data first shared with the public in June 2020. Researchers found that the MiniMed 780G was linked to a time in range of 78.8%.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.